

CURRICULUM VITAE

รองศาสตราจารย์ ดร. เกษักร ชลภัทร สุขเกษม

Associate Professor. B. Pharm, Ph.D. CHONLAPHAT SUKASEM

หน่วยงานที่สังกัด

ภาควิชา / คณะภาควิชาพยาธิวิทยา/คณะแพทยศาสตร์ โรงพยาบาลรามาธิบดี

ที่อยู่ติดต่อ ห้องปฏิบัติการเภสัชพันธุศาสตร์และการรักษาเฉพาะบุคคล

ภาควิชาพยาธิวิทยา คณะแพทยศาสตร์ โรงพยาบาลรามาธิบดี

Tel: 02-2011380, 02-2011390 Fax: 02-2011390

E-mail: Chonlaphat.suk@mahidol.ac.th, Chonlaphat_suk@hotmail.com



| ระดับ | คณะ/สถาบันที่จบ | สาขา | ประเทศ | ปีที่จบ |
|------------------------------|--|-----------------------|----------|---------------|
| ปริญญาตรี | เภสัชศาสตร์/ มหาวิทยาลัยรังสิต | เภสัชศาสตร์ | ไทย | 2544 |
| ปริญญาโท | Keller of Graduated School of | Project Management | U.S.A. | 2548 |
| ปริญญาเอก | วิทยาศาสตร์/มหาวิทยาลัยมหิดล | พยาธิชีววิทยา | ไทย | 2550 |
| หลังปริญญา เอก | -Faculty of Medicine/ Universite' Francois-Rabelais | HIV-1 Pseudovirus | ฝรั่งเศส | 2550- 2551 |
| (Postdoctoral fellowship) | -Laboratory for Cardiovascular Diseases/ RIKEN Center for Genomics Medicine | Pharmacogenomics | ญี่ปุ่น | 2552- 2553 |

งานที่เชี่ยวชาญ

1. Biosafety /Biosecurity/ Bioterrorism
2. HIV-1 drug resistance testing (Phenotype, Genotype and Virtual Phenotype)
3. Pharmacogenetic testing (Genotype-Phenotype correlation)

งานที่สนใจ

1. HIV-1 drug resistance
2. Molecular Virology and subtyping
3. Pharmacogenetics and personalized medicine

ประวัติผลงานด้านอื่นๆ

1. เลขาธิการ เครือข่ายความปลอดภัยและความมั่นคงทางชีวภาพ (ประเทศไทย)
2. คณะกรรมการบริหาร สมาคมไวรัสวิทยา (ประเทศไทย)

รางวัลที่ได้รับ

ผลงานวิจัยดีเด่นประจำปี 2544 งานวิจัยดีเด่น (สาขาเภสัชศาสตร์) จากมหาวิทยาลัยรังสิต
“Study of hepatotoxicity of *Cassia Siamea Lamk* in Rat”

Publication (ปัจจุบัน – อดีต)

1. Yaowakulpatana K, Vadcharavivad S, Ingsathit A, Areepium N, Kantachuvesiri S, Phakdeekitcharoen B, **Sukasem C**, Sra-Ium S, Sumethkul V, Kitiyakara C. [Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.](#) Eur J Clin Pharmacol. 2015 Dec 4. [Epub ahead of print]
2. Damronglerd P, **Sukasem C**, Thipmontree W, **Puangpetch A**, Kiertiburanakul S. [A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.](#) Pharmgenomics Pers Med. 2015 Oct 3;8:155-162. eCollection 2015.
3. Bushyakanist A, Puangpetch A, **Sukasem C**, Kiertiburanakul S. [The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand.](#) Pharmgenomics Pers Med. 2015 Nov 5;8:163-170. eCollection 2015.
4. Suwalak T, Srisawasdi P, Puangpetch A, Santon S, Koomdee N, Chamnanphon M, Charoenyingwattana A, Chantratita W, **Sukasem C**. [Polymorphisms of the ApoE \(Apolipoprotein E\) Gene and Their Influence on Dyslipidemia in HIV-1-Infected Individuals.](#) Jpn J Infect Dis. 2015 Jan 26;68(1):5-12. doi: 10.7883/yoken.JJID.2013.190.
5. Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, Chamkrachchangpada B, Tan-kam T, Limsila P, **Sukasem C**. [Serum Prolactin level in Thai Children and Adolescents with Autistic Spectrum Disorder on Long Term Risperidone Treatments.](#) Thai J Pharmacol. 2015; 36(1): 26-35.

6. Vanwong N, Medhasi S, Pongchaidecha M, Ngamsamut N, Puangpetch A, Chamnanphon M, Chamkrachchangpada B, Tan-kam T, Hongkaew Y, Limsila P, **Sukasem C.**[Pharmacogenetics and Clinical Risk Factors for Risperidone-Related Weight Gain in Thai Autistic Spectrum Disorder Patients.](#) Thai J Pharmacol. 2015; 36(1): 13-25.
7. Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, **Sukasem C**, Wananukul W.[Pharmacokinetics of mitragynine in man.](#)Drug Des Devel Ther. 2015 Apr 29;9:2421-9. doi: 10.2147/DDDT.S79658. eCollection 2015.
8. Puangpetch A, Koomdee N, Chamnanphol M, Jantararoungtong T, Santon S, Prommas S, Hongkaew Y, **Sukasem C.**[HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity.](#)Front Genet. 2015 Jan 22;5:478. doi: 10.3389/fgene.2014.00478. eCollection 2014.
9. Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, Chamkrachchangpada B, Tan-Kam T, Limsila P, **Sukasem C.**[Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone.](#)Neuropsychiatr Dis Treat. 2015 Jan 22;11:191-6. doi: 10.2147/NDT.S76276. eCollection 2015.
10. **Sukasem C**, Atasilp C, Chansriwong P, Chamnanphon M, Puangpetch A, Sirachainan E.[Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers.](#)J Clin Lab Anal. 2014 Dec 26. doi: 10.1002/jcla.21820. [Epub ahead of print]
11. Suwalak T, Srisawasdi P, Puangpetch A, Santon S, Koomdee N, Chamnanphon M, Charoenyingwattana A, Chantratita W, **Sukasem C.**[The distribution of Apolipoprotein E gene polymorphism and their influences in dyslipidemias in HIV-1 infections.](#)Jpn J Infect Dis. 2014 Nov 25. [Epub ahead of print]
12. Manosuthi W, **Sukasem C**, Thongyen S, Nilkamhang S, Sungkanuparph S.[ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.](#)J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129.
13. **Sukasem C**, Chamnanphon M, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Puangpetch A, Manosuthi W.[Pharmacogenetics and Clinical Biomarkers for Subtherapeutic](#)

- [Plasma Efavirenz Concentration in HIV-1 Infected Thai Adults](#). Drug Metab Pharmacokinet. 2014 Aug 25;29(4):289-95.
14. **Sukasem C**, Puangpetch A, Medhasi S, Tassaneeyakul W. [Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation](#). Asian Pac J Allergy Immunol. 2014 Jun;32(2):111-23.
 15. **Sukasem C**, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Chamnanphol M, Puangpetch A, Sungkanuparph S. [Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism](#). Infection. 2014 Jun;42(3):469-74. doi: 10.1007/s15010-013-0560-6.
 16. Manosuthi W, **Sukasem C**, Thongyen S, Nilkamhang S, Sungkanuparph S. [ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen](#). J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129. Epub 2014 Apr 30.
 17. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy](#). Int J Antimicrob Agents. 2014 Mar;43(3):292-6. doi: 10.1016/j.ijantimicag.2013.10.022.
 18. Manosuthi W, **Sukasem C**, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [CYP2B6 18492T>C polymorphism compromises efavirenz concentration in co-infected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1](#). Antimicrob Agents Chemother. 2014 Apr;58(4):2268-73. doi: 10.1128/AAC.02384-13. Epub 2014 Feb 3.
 19. **Sukasem C**, Chamnanphon M, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Puangpetch A, Manosuthi W. [Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults](#). Drug Metab Pharmacokinet. 2014 Jan 28. [Epub ahead of print]
 20. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy](#). Int J Antimicrob Agents. 2014 Mar;43(3):292-6. doi: 10.1016/j.ijantimicag.2013.10.022.
 21. **Sukasem C**, Chamnanphon M, Koomdee N, Santon S, Jantararoungtong T, Prommas S, **Puangpetch A**, Manosuthi W. [Pharmacogenetics and clinical biomarkers for subtherapeutic](#)

- [plasma efavirenz concentration in HIV-1 infected Thai adults](#). Drug Metab Pharmacokinet. 2014 Jan 28. [Epub ahead of print]
22. **Sukasem C**, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Chamnanphol M, Puangpetch A, Sungkanuparph S. [Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism](#). Infection. 2013 Nov 30. [Epub ahead of print]
23. Wongkittichote P, **Sukasem C**, Kikuchi A, Aekplakorn W, Jensen LT, Kure S, Wattanasirichaigoon D. [Screening of SLC25A13 mutation in the Thai population](#). World J Gastroenterol. 2013 Nov 21;19(43):7735-42. doi: 10.3748/wjg.v19.i43.7735.
24. **Sukasem C**, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P. [CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors](#). Pharmgenomics Pers Med. 2013 Aug 22;6:85-91. doi: 10.2147/PGPM.S42332.
25. Sensorn I, Sirachainan E, Chamnanphon M, **Pasomsub E**, Trachu N, Supavilai P, **Sukasem C**, Pinthong D. [Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen](#). Pharmgenomics Pers Med. 2013 Aug 26;6:93-8. doi: 10.2147/PGPM.S44006
26. Tunthong R, Vathesatogkit P, **Sukasem C**, **Puangpetch A**, **Chantratita W**, Angchaisuksiri P, Sura T, Pathumarak A, Yamwong S, Boonbaichaiyapruck S, Sritara P. Pharmacogenetic study of CYP 2C19 and clopidogrel dose adjustment according to platelet reactivity monitoring in atherothrombotic-risk patients in Thailand. Curr Pharmacogenomics Person Med. 2013; 11: 154-161.
27. **Srisawasdi P**, Suwalak T, **Sukasem C**, **Chittamma A**, Pocathikorn A, **Vanavanan S**, Puangpetch A, Santon S, Chantratita W, Kiertiburanakul S, Kroll MH. [Small-Dense LDL Cholesterol/Large-Buoyant LDL Cholesterol Ratio as an Excellent Marker for Indicating Lipodystrophy in HIV-Infected Patients](#). Am J Clin Pathol. 2013 Oct;140(4):506-15. doi: 10.1309/AJCPE5I3KELTBXEJ.
28. **Sukasem C**, Gatrungei M, Promso S, Cunningham P, Koomdee N, Chamnanphon M, Chantratita W. Pharmacogenetic testing for Abacavir Hypersensitivity screening in resource limited setting. Curr Pharmacogenomics Person Med. 2013 (Accepted and In press).

29. Sensorn I, Jantararoungtong T, Sirachainan E, Chamnanphol M, Trachu N, **Pasomsub E**, Supavilai P, Pinthong D, **Sukasem C**. Association of CYP3A, ABCB1 and ABCC2 Polymorphisms and Clinical outcomes of Thai Breast cancer Patients treated with Tamoxifen. *Pharmgenomics Pers Med*. 2013. (Accepted and In press).
30. **Sukasem C**, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P. [CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors](#). *Pharmgenomics Pers Med*. 2013 Aug 22;6:85-91. doi: 10.2147/PGPM.S42332
31. Suwannarat P, Chamnanphon M, Ngamsamut N, Sinrachatanant A, Chamkrachchangpada B, Tan-kam T, **Puangpetch A**, **Sukasem C**, Limsila P. Molecular genetic analysis of CYP2D6 and HLA-B*15:02 in Thai autistic spectrum disorder children: Implication for pharmacogenetics testing and optimization of drug treatments. *Thai J. Genet*. 2013, 6(1) : 81-85.
32. **Sukasem C**, Sungkanuparph S. [Would a CYP2B6 test help HIV patients being treated with efavirenz?](#) *Pharmacogenomics*. 2013 Jul;14(9):999-1001. doi: 10.2217/pgs.13.69. No abstract available.
33. Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, **Chantratita W**, **Pasomsub E**, Noonpakdee W, Sensorn I, **Sukasem C**. [Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen](#). *Pharmgenomics Pers Med*. 2013 May 24;6:37-48. doi: 10.2147/PGPM.S42330. Print 2013.
34. Tan-Kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, **Sukasem C**. [Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report](#). *Pharmgenomics Pers Med*. 2013;6:3-7. doi: 10.2147/PGPM.S36782. Epub 2013 Jan 11
35. **Sukasem C**, Chamnanphon M, Koomdee N, Puangpetch A, Santon S, Jantararoungtong T, Prommas S, **Chantratita W**, Manosuthi W. [High Plasma Efavirenz Concentration and CYP2B6 Polymorphisms in Thai HIV-1 Infections](#). *Drug Metab Pharmacokinet*. 2013 Oct 25;28(5):391-7.
36. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [Impact of Pharmacogenetic Markers of CYP2B6](#),

- [Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients](#). *Antimicrob Agents Chemother*. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17
37. **Sukasem C**, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. [Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults](#). *Br J Clin Pharmacol*. 2012 Dec;74(6):1005-1012. doi: 10.1111/j.1365-2125.2012.04288.x.
38. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis Co-Infected Patients](#). *Antimicrob Agents Chemother*. 2012 Dec 17. [Epub ahead of print]
39. Manosuthi W, **Sukasem C**, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. [Impact of pharmacogenetic markers of CYP2B6 and clinical factors on plasma efavirenz level in HIV/tuberculosis co-infected Thai patients](#). *J Int AIDS Soc*. 2012 Nov 11;15(6):18410. doi: 10.7448/IAS.15.6.18410
40. Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, **Sukasem C**. [CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients](#). *Pharmgenomics Pers Med*. 2012;5:149-53. doi: 10.2147/PGPM.S32160. Epub 2012 Oct 17.
41. Punyacam P, Iemwimangsa N, Chantratita W, **Sukasem C**, Sungkanuparph S. [HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures](#). *Curr HIV Res*. 2012 Apr;10(3):271-4.
42. Sungkanuparph S, **Sukasem C**, Kiertiburanakul S, Pasomsub E, Chantratita W. [Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand](#). *J Int AIDS Soc*. 2012 Mar 12;15(1):12.
43. Punyacam P, Iemwimangsa N, Chantratita W, **Sukasem C**, Sungkanuparph S. [HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures](#). *Curr HIV Res*. 2012 Apr;10(3):271-4.

44. Sungkanuparph S, **Sukasem C**, Kiertiburanakul S, Pasomsu E, Chantratita W. [Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand.](#) J Int AIDS Soc. 2012 Mar 12;15(1):12.
45. Sungkanuparph S, Kiertiburanakul S, **Sukasem C**, Chantratita W. [Discrepancies Between WHO 2009 and IAS-USA 2009 Lists for Determining the Rate of Transmitted HIV-1 Drug Resistance: A Prospective Study.](#) J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):e3-5. No abstract available.
46. Chantratita W, **Sukasem C**, Sirinavin S, Sankuntaw N, Srichantaratsamee C, Pasomsu E, Malathum K. Simultaneous detection and subtyping of H274Y-positive influenza A (H1N1) using pyrosequencing. J Infect Dev Ctries. 2011 May 28;5(5):348-52.
47. Pongthanapisith V, **Sukasem C**, Premchaiporn K, Srichantaratsamee C, Chantratita W. Clinical performance of three rapid diagnostic tests for influenza virus in nasopharyngeal specimens to detect novel swine-origin influenza viruses. Infection. 2011 Apr;39(2):105-11. Epub 2011 Mar 22
48. **Sukasem C**, Pairoj W, Saekang N, Pombubpha H, Srichunrasami C, Pongtippan A, Junyangdikul P, Chantratita W. Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer: will a quadrivalent vaccine be necessary in Thailand? J Med Virol. 2011 Jan;83(1):119-26.
49. Manosuthi W, Butler DM, Chantratita W, **Sukasem C**, Richman DD, Smith DM. Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine. AIDS Res Hum Retroviruses. 2010 May 27. [Epub ahead of print] No abstract available.
50. Pasomsu E, **Sukasem C**, Sungkanuparph S, Kijisirikul B, Chantratita W. The application of artificial neural networks for phenotypic drug resistance prediction: evaluation and comparison with other interpretation systems. Jpn J Infect Dis. 2010 Mar;63(2):87-94
51. Kiertiburanakul S, Wiboonchutikul S, **Sukasem C**, Chantratita W, Sungkanuparph S. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J Clin Virol. 2010 Apr;47(4):330-4. [Epub 2010 Feb 24]

52. Sungkanuparph S, **Sukasem C**, Manosuthi W, Wiboonchutikul S, Piyavong B, Chantratita W. Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection. *J Clin Virol.* 2008 Nov;43(3):284-6.
53. Chantratita W, **Sukasem C**, Kaewpongsri S, Srichunrusami C, Pairoj W, Thitithanyanont A, Chaichoune K, Ratanakron P, Songserm T, Damrongwatanapokin S, Landt O. Qualitative detection of avian influenza A (H5N1) viruses: A comparative evaluation of four real-time nucleic acid amplification methods. *Mol Cell Probes.* 2008 Oct-Dec;22(5-6):287-93.
54. **Sukasem C**, Churdboonchart V, Sukeepaisarncharoen W, Piroj W, Inwisai T, Tiensuwan M, Chantratita W. Genotypic resistance profiles in antiretroviral-naïve HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. *Int J Antimicrob Agents.* 2008 Mar;31(3):277-81.
55. **C. Sukasem**, V. Churdboonchart, S. Chasombat, S. Kohreanudom, C. Watitpun, E. Pasomsub, W. Piroj, M. Tiensuwan, W. Chantratita. Surveillance of genotypic resistance mutations in HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. *Infection*, 2007; 35: 81-88.
56. **C. Sukasem**, V. Churdboonchart, S. Chasombat, S. Kohreanudom, C. Watitpun, W. Piroj, M. Tiensuwan, W. Chantratita. Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: under the initiative of access to the NNRTI-based regimen in Thailand. *Journal of Chemotherapy*, 2007; 19: 528-533.
57. **C. Sukasem**, V. Churdboonchart, K. Sirisidhi, S. Riengrojpitak, S. Chasombat, C. Watitpun, W. Piroj, M. Tiensuwan and W. Chantratita. Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drug in Thailand: Implication for further epidemiologic surveillance, *Japanese Journal of Infectious Diseases*, 2007; 60: 284-289.
58. **C. Sukasem**, V. Churdboonchart, W. Sukeepaisarncharoen, W. Piroj, T. Inwisai, M. Tiensuwan, W. Chantratita. Genotypic resistance profiles in antiretroviral-naïve HIV-1 infections before and after initiation of first-line HAART: Impact of polymorphism on therapy resistance, *International Journal of Antimicrobial Agent and Chemotherapy*, 2008; 31: 277-281.
59. W. Chantratita, **C. Sukasem**, S. Kaewpongsri, C. Srichunrusami, W. Pairoj, A. Thitithanyanont, K. Chaichoune, P. Ratanakron, T. Songserm, S. Damrongwatanapokin, O.

Landt . Qualitative detection of avian influenza A (H5N1) viruses: a comparative evaluation of four real time nucleic acid amplification methods. Molecular and Cellular probe, 2008.

60.S Sungkanuparph, **C. Sukasem**, W Manosuthi, S Wiboonchutikul, B Piyavong and W Chantratita. Tipranavir resistance in protease inhibitor-naïve patients with HIV-1 subtype A/E infection. Journal of Clinical Virology, 2008; 43:284-6.

Textbook

1. Maximize the effectiveness of HIV-1 treatment by using molecular techniques, bioinformatics and Pharmacogenomics edited by W. Chantratita (2007), ISBN 9789740456797, **Chonlaphat Sukasem** and Wasun Chantratita, 8 years monitoring of HIV-1 drug resistance in Thailand: the application of molecular technique and bioinformatics, 86-114.
2. Use of bioinformatics for extensive genome analysis edited by W. Chantratita, **C. Sukasem** and S. Mahasirimongkon. (2008), ISBN 9789743499975, **Chonlaphat Sukasem**, Pharmacogenetic testing and its application for Public Health in Thailand, 384-410.
3. Influenza A virus 2nd editor, edited by P. Bhattarakosol and P. Auewarakul (2008), ISBN 9749495039, Chonlaphat Sukasem, Biosafety Laboratory Level 3: the need for Avian influenza working. (In press).

International and National Presentation

- Oral presentation " The presence of anti-R7V antibodies in HIV-infected patients: a novel marker for the non-progression to AIDS", 8th International meeting on molecular epidemiology and evolutionary genetics in infectious diseases, Bangkok, Thailand; 2006.
- Oral presentation "Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand", 2nd meeting on HIV drug resistance workshop: Basic principles and clinical implications, Bangkok, Thailand; 2007.
- Oral presentation 13th meeting on "AIDS and Flow cytometry, 2007" Thailand